Aarey Drugs & Pharmaceuticals Limited has made a regulatory disclosure to BSE Limited and National Stock Exchange of India Limited regarding compliance with SEBI Listing Regulations.
The company has issued physical letters to shareholders whose email addresses are not registered with the Company/Depository Participants as of the cut-off date of Friday, 4th September, 2026. These letters provide the web link from where the Integrated Annual Report for Financial Year 2025-26 can be accessed on the Company's website.
The 36th Annual General Meeting of the company is scheduled to be held on Wednesday, 30th September, 2026 at 03:00 PM (IST) through Video Conferencing facility/Other Audio Visual Means.
The exact web path where the Annual Report 2025-26 is available is: http://www.aareydrugs.com/investors.html
The disclosure is made in terms of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Shareholders are encouraged to update their email addresses through their depository participants for electronic holding or by communicating with the company/their RTA to facilitate future electronic communication.
The letter was signed by Nimit Ghatalia, Director (DIN: 07069841) for the main disclosure to exchanges, and by Mr. Kailash Chand Jethlia, Company Secretary & Compliance Officer for the shareholder communication.
Investor queries can be directed to investorgrievance@aareydrugs.com or 02239829999.